Background Effective response to emerging pandemic threats is complicated by the need to
develop specific vaccines and other medical products. The availability of broadly specific …

We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical
trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion …

The severe COVID‐19 pandemic drives the research toward the SARS‐CoV‐2 virion
structure and the possible therapies against it. Here, we characterized the β‐propiolactone …

We present the results of a randomized, double-blind, placebo-controlled, multi-center
clinical trial of the tolerability, safety, and immunogenicity of the inactivated whole virion …

The unprecedented in recent history global COVID-19 pandemic urged the implementation
of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to …

Objectives The outbreak of coronavirus disease 2019 (COVID-19) started in December 2019
in China and then spread worldwide over the following months, involving 188 countries. …

Many viruses are known to trigger endoplasmic reticulum (ER) stress in host cells, which in
turn can develop a protective unfolded protein response (UPR). Depending on the conditions…

Various types of COVID-19 vaccines, including adenovirus, mRNA, and inactivated ones,
have been developed and approved for clinical use worldwide. Inactivated vaccines are …

The EMCV L and 2A proteins are virulence factors that counteract host cell defense mechanisms.
Both L and 2A exhibit antiapoptotic properties, but the available data were obtained in …

Global polio eradication requires both safe and effective vaccines, and safe production
processes. Sabin oral poliomyelitis vaccine (OPV) strains can evolve to virulent viruses and result …